Why Is JANUX THERAPEUTICS I (JANX) Stock Moving Today?

Janux Therapeutics stock fell 27.62% to close at $12.76 on Monday. The sharp decline followed the company’s announcement of positive initial Phase 1 data for its lead candidate, JANX011, in healthy volunteers. Despite the favorable clinical results, the market reaction was negative, with the stock printing 13 fresh 52-week lows during the session.

What Happened

Janux Therapeutics disclosed preliminary findings from its Phase 1 trial of JANX011 in healthy participants on November 9, 2026. The data provided clinical validation for the company’s ARM platform in autoimmune diseases, supporting the planned development of the drug in patients with the condition. The company outlined its autoimmune development strategy during a discussion of the healthy volunteer data.

Market reaction to the news was mixed. While the data was described as positive, the stock experienced a significant selloff. William Blair characterized the selloff as overdone. Other analysts adjusted their views in response to the data. Truist Securities maintained a Buy rating on the stock and raised its price target to $27. Barclays and Wedbush also updated their price targets for Janux Therapeutics following the announcement.

What The Data Shows

The stock closed at $12.76, near the bottom of its 52-week range, which spans from $12.12 to $35.34. The company has a market capitalization of $1.1 billion and remains unprofitable, with a trailing twelve-month EPS of -1.59. Revenue grew 132.9% over the trailing twelve months, but the net margin stands at -428.7%. The stock exhibits high volatility, with a beta of 2.39. On the day of the announcement, the stock printed 13 fresh 52-week lows, indicating sustained selling pressure throughout the session.

What To Watch

Investors will monitor the company’s next scheduled earnings date for further updates on the JANX011 development timeline. Analyst coverage remains active, with recent price target adjustments from Truist Securities, Barclays, and Wedbush providing a range of valuation perspectives for the stock.

Why is JANX stock moving today?

JANUX THERAPEUTICS I (JANX) is drawing unusual attention today. Our newswire has captured 2 stories on JANX across 2 sources in the last 36 hours, with AI sentiment reading bearish (avg 34/100). The most recent driver: "JANX Downgraded by Wolfe Research -- Current Rating: Peer Perform" (GuruFocus).

Is JANX a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of JANX coverage reads 34/100 over 2 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.